# DeepCure

> DeepCure is a Boston-based biotech that uses AI, physics-based simulation, and automated robotic chemistry to design novel small-molecule drugs for hard-to-treat immune and inflammatory diseases. Founded in 2018 by MIT Media Lab researchers, the company pairs deep learning with a proprietary chemical database of up to 10^18 synthesizable compounds and an in-house automated wet lab, aiming to turn AI-generated molecules into real, testable, first-in-class therapies.

- **Founded:** 2018
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Kfir Schreiber (Co-Founder & CEO), Thrasyvoulos Karydis (Co-Founder & CTO), Joseph Jacobson (Co-Founder)
- **Team size:** ~29 employees
- **Products:** AI + automated synthesis discovery platform, Proprietary chemical database, DC-9476, DC-15442
- **Notable:** Selected its first fully AI-generated development candidate, DC-9476, in 2024, Presented in vivo data showing DC-9476 outperformed anti-TNF, anti-IL6, and JAK (tofacitinib) therapy in a collagen-induced arthritis mouse model at ACR Convergence 2024, Built an in-house automated synthesis (robotic wet lab) capability that turns AI designs into physical, testable compounds

## Products & services

- **AI + automated synthesis discovery platform** — An integrated engine pairing deep learning and physics-based simulation with cloud computing and an in-house automated robotic wet lab, so AI-generated molecules can be synthesized and tested in days rather than outsourced and waited on.
- **Proprietary chemical database** — A searchable library of up to 10^18 synthesizable, drug-like compounds used to ground generative design in molecules that can actually be made.
- **DC-9476** — Third-generation, selective BRD4 BD2 inhibitor and the company's first AI-generated development candidate, targeting autoimmune diseases including rheumatoid arthritis, Still's disease, and macrophage activation syndrome.
- **DC-15442** — Oral STAT6 inhibitor reported to achieve 100% in vivo inhibition of pSTAT6 with efficacy comparable to dupilumab across disease models, aimed at asthma and atopic dermatitis.

## Achievements

- Selected its first fully AI-generated development candidate, DC-9476, in 2024
- Presented in vivo data showing DC-9476 outperformed anti-TNF, anti-IL6, and JAK (tofacitinib) therapy in a collagen-induced arthritis mouse model at ACR Convergence 2024
- Built an in-house automated synthesis (robotic wet lab) capability that turns AI designs into physical, testable compounds
- Raised $64.6M total across Series A and Series A-1
- Assembled a proprietary chemical search space of up to 10^18 synthesizable compounds

## Latest updates

- **2024-04** — Raised $24.6M Series A-1 led by IAG Capital Partners to advance AI-driven drug discovery.
- **2024-08** — Announced DC-9476 as its first AI-generated development candidate for autoimmune diseases; launched Leeds Institute collaboration.
- **2024-09** — Presented in vivo efficacy and safety data for DC-9476 in macrophage activation syndrome at the EMBO Conference.
- **2024-10** — Presented first ex vivo rheumatoid arthritis patient data for DC-9476 at ACR Convergence 2024.
- **2025** — DC-9476 expected to progress toward clinical trials; pipeline expanding to STAT6 (asthma, atopic dermatitis) and an undisclosed inflammatory target.

## Links

- Website: https://deepcure.com
- LinkedIn: https://www.linkedin.com/company/deepcure
- Twitter/X: https://twitter.com/DeepCureAI

---

Profile page: https://yespress.io/deepcure
Published by YesPress — https://yespress.io
Last updated: 2026-06-15